{"id":3458,"date":"2026-02-18T16:20:50","date_gmt":"2026-02-18T15:20:50","guid":{"rendered":"https:\/\/www.amsvita.com\/en\/?p=3458"},"modified":"2026-03-28T16:21:28","modified_gmt":"2026-03-28T15:21:28","slug":"autologous-regenerative-approach-in-degenerative-disorders","status":"publish","type":"post","link":"https:\/\/www.amsvita.com\/en\/news\/autologous-regenerative-approach-in-degenerative-disorders\/","title":{"rendered":"Autologous Regenerative Approach in Degenerative Disorders"},"content":{"rendered":"\n

Limitations of symptomatic treatments<\/strong><\/h2>\n\n\n\n

Degenerative joint diseases such as osteoarthritis<\/strong> (OA) are characterized by progressive degeneration of articular cartilage, joint pain, stiffness, and functional limitation, ultimately leading to disability and impaired quality of life. In OA, the disease process reflects an imbalance between tissue repair and destruction in joints with intrinsically poor healing potential, related in part to limited vascularization and lack of direct access to bone marrow progenitor cells. This biological context underpins the limited capacity of conventional symptomatic treatments to modify the structural course of the disease.<\/p>\n\n\n\n

Conservative management of OA typically includes physical therapy, weight loss, lifestyle modification, pharmacologic therapies, intra-articular steroid injections, intra-articular hyaluronic acid injections, and, in advanced stages, surgical procedures such as joint replacement. These approaches are largely directed at pain relief, optimization of joint biomechanics, and preservation of mobility and independence. Goals include reducing symptom burden, slowing functional decline, and delaying arthroplasty, but they do not primarily target regeneration of damaged cartilage or restoration of joint homeostasis.<\/p>\n\n\n\n

A key limitation of these symptomatic strategies is that none of them reverses or repairs the degenerative nature of OA. Pharmacologic agents and intra-articular injectables can reduce inflammation and pain, but they do not provide a source of progenitor cells or a sustained regenerative stimulus to articular cartilage, subchondral bone, or periarticular soft tissues. As a result, structural progression of disease may continue despite symptomatic improvement, and many patients ultimately progress to surgical intervention.<\/p>\n\n\n\n

The economic and quality-of-life impact of OA is substantial, and the expected increase in disease burden with population aging and rising obesity further highlights the limitations of purely symptomatic care. In this context, there is growing interest in therapeutic approaches that can address underlying tissue degeneration. Autologous regenerative strategies based on mesenchymal stromal cells (MSCs) and adipose-derived stem cells (ADSCs) have emerged as potential options to complement or, in selected cases, delay traditional symptomatic and surgical treatments by aiming to stimulate repair and modulate the joint microenvironment.<\/p>\n\n\n\n

Regenerative targets in degenerative diseases<\/strong><\/h2>\n\n\n\n

Autologous regenerative therapy in degenerative musculoskeletal disorders is conceptually directed at tissues with limited intrinsic healing capacity, including articular cartilage<\/strong>, subchondral bone, tendons, and periarticular soft tissues. In OA, the primary target is the degenerated articular cartilage of weight-bearing joints such as the knee and hip, where chronic mechanical stress, biochemical alterations, and inflammatory mediators contribute to progressive cartilage loss and joint dysfunction. The poor vascularization of cartilage and the absence of direct access to bone marrow progenitor cells contribute to the limited spontaneous repair potential.<\/p>\n\n\n\n

Adipose tissue has been identified as a clinically accessible reservoir of multipotent mesenchymal stromal cells with regenerative potential. Zuk and colleagues described human adipose tissue as a source of multipotent MSCs similar to those found in bone marrow, leading to the recognition of adipose-derived stem cells as a key component of the stromal vascular fraction (SVF). These cells, together with associated cytokines, growth factors, pre-adipocytes, and mature adipocytes, constitute a biologically active graft capable of influencing multiple tissue compartments within a degenerative joint.<\/p>\n\n\n\n

Within the context of degenerative joint disease, ADSCs and other SVF components are considered relevant for their capacity to differentiate into chondrocytes, osteogenic cells, and endothelial cells, and for their paracrine activity. The regenerative targets therefore extend beyond cartilage to include subchondral bone remodeling, synovial membrane modulation, and support of periarticular soft tissues. In addition, the lubricating properties of autologous fat micrografts may contribute to improved joint biomechanics and symptom relief in OA.<\/p>\n\n\n\n

More broadly, micro-fragmented adipose tissue rich in SVF and ADSCs has been proposed as a promising source for regenerative treatments in degenerative diseases or disorders that are not adequately controlled by conventional care. In this setting, the therapeutic focus is on delivering viable stromal and progenitor cells to damaged tissues in a minimally manipulated, autologous form, with the aim of enhancing local repair processes, modulating inflammation, and supporting angiogenesis in compromised microenvironments.<\/p>\n\n\n\n

Mechanisms of action of autologous therapy<\/strong><\/h2>\n\n\n\n

Autologous Regenerative Therapy (ART) is defined as an innovative medical discipline that aims to regenerate injured tissues or stimulate their repair using the patient\u2019s own cells in a single medical procedure. The central cellular component is the mesenchymal stromal cell<\/strong>, whose hallmark is the ability to differentiate according to signals from the surrounding environment and specific growth factors. This plasticity allows MSCs, including ADSCs, to contribute to the healing of lesions involving different tissues such as cartilage, tendon, and bone.<\/p>\n\n\n\n

Adipose-derived stem cells are particularly enriched in the stromal vascular fraction of adipose tissue and have been shown to differentiate into multiple lineages, including adipogenic, chondrogenic, osteogenic, myogenic, hepatogenic, and endothelial phenotypes, in vitro and in vivo. In addition to direct differentiation, ADSCs secrete bioactive molecules that stimulate angiogenesis and exhibit antifibrotic, antiapoptotic, and immunomodulatory properties. These paracrine effects are considered critical for modulating the inflammatory milieu of degenerative joints and supporting tissue remodeling.<\/p>\n\n\n\n

Micro-fragmented adipose tissue grafts, obtained through minimally invasive harvesting and minimal manipulation, preserve a complex tissue architecture containing viable adipocytes, stromal cells, pericytes, and endothelial progenitors. Studies evaluating adipose tissue harvested with small-port microcannulas have demonstrated that such tissue contains viable and proliferative cells, with cell viability comparable to that of tissue processed by enzymatic digestion. This supports the concept that mechanically processed, autologous adipose tissue can serve as a biologically active scaffold delivering SVF cells directly to degenerative sites.<\/p>\n\n\n\n

Intra-articular injection of autologous micro-fragmented adipose tissue in OA combines several mechanisms: provision of ADSCs and other SVF cells with regenerative and immunomodulatory potential, delivery of growth factors and cytokines, and a natural lubricating effect of the fat graft on the joint surfaces. Collectively, these mechanisms aim to reduce pain, improve joint function, and potentially influence the progression of degenerative changes by enhancing local repair responses and improving the quality of the joint microenvironment.<\/p>\n\n\n\n

Examples: OA, tendinopathies, disc degeneration<\/strong><\/h2>\n\n\n\n

Among degenerative disorders, osteoarthritis<\/strong> of the knee and hip is the best-characterized indication for autologous micro-fragmented adipose tissue therapy in the available clinical data. In an observational cohort, 250 patients with initial-stage degenerative OA of the hip and\/or knee underwent intra-articular injection of autologous fat micrograft processed with a dedicated device. The majority of procedures involved the knee, with the remainder targeting the hip, reflecting the high prevalence of OA in these weight-bearing joints.<\/p>\n\n\n\n

In this cohort, the rationale for treatment was based on the reparative potential of autologous fat grafts on damaged joint tissues and their lubricating effect. Patients presented with articular pain and radiographically confirmed early degenerative changes according to established grading systems for hip and knee OA. Clinical follow-up demonstrated improvements in range of motion and stiffness, as well as reductions in pain intensity over time, supporting the feasibility of this autologous regenerative approach in OA.<\/p>\n\n\n\n

Beyond OA, micro-fragmented adipose tissue and SVF-based therapies have been explored in other degenerative or chronic conditions, including applications in skin trophism, complex wounds, and tissue damage after radiotherapy, where adipose tissue implantation has been used to accelerate healing and improve tissue quality. These experiences, although not focused on tendinopathies or disc degeneration, illustrate the broader regenerative potential of adipose-derived cell populations in mesenchymal tissues.<\/p>\n\n\n\n

Regenerative therapy based on micro-fragmented adipose tissue has been described as a promising treatment for degenerative diseases or disorders that cannot be successfully managed through conventional care. While the detailed clinical evidence in tendinopathies and disc degeneration is not elaborated in the available documents, the shared pathophysiological features of limited intrinsic healing and mesenchymal tissue degeneration provide a conceptual basis for extending autologous adipose-derived approaches to these indications within appropriate research and clinical frameworks.<\/p>\n\n\n\n

Clinical protocols and monitoring<\/strong><\/h2>\n\n\n\n

In the reported OA cohort, autologous micro-fragmented adipose tissue therapy was delivered as a single-session procedure performed in a private practice setting under the principles of the Declaration of Helsinki. The process included harvesting donor adipose tissue, isolating the stromal vascular fraction within a fat micrograft using a dedicated device, and intra-articular injection into the affected knee or hip. The entire procedure required approximately 60 to 70 minutes.<\/p>\n\n\n\n

Inclusion criteria encompassed men and women aged 20 to 80 years with articular pain of the hips and\/or knees and radiographic evidence of initial-stage degenerative OA. OA severity was graded using the T\u00f6nnis classification for the hip and the Kellgren\u2013Lawrence classification for the knee, allowing stratification of patients according to structural disease stage. Pre-treatment imaging included X-rays and magnetic resonance imaging of the symptomatic joint to evaluate and grade OA and to support treatment planning.<\/p>\n\n\n\n

Postoperative monitoring involved scheduled clinical assessments at one, three, six, and twelve months after the intra-articular injection. Outcome measures included range of motion (ROM), joint stiffness as reported by patients, and pain intensity measured using the Visual Analog Scale (VAS) at three, six, and twelve months. Health-related quality of life was evaluated in a subset of patients using the SF-12 questionnaire, generating physical (PCS-12) and mental (MCS-12) component scores.<\/p>\n\n\n\n

Safety monitoring addressed both donor and recipient sites. The donor site postoperative course was generally uneventful, with minimal discomfort, edema, and ecchymosis, and no major complications such as infection reported. At the injected joint, postoperative findings were limited to transient swelling and low-grade pain for three to seven days, without observed adverse events or infections. The autologous nature of the injected material was associated with good local tolerability in this cohort.<\/p>\n\n\n\n

Therapeutic outcomes and evidence<\/strong><\/h2>\n\n\n\n

In patients with hip and knee OA treated with intra-articular autologous fat micrograft, clinical improvement was observed in multiple domains. Range of motion of the treated joints increased by an average of 10 degrees at three months, accompanied by a reduction in stiffness as reported by patients. Pain intensity, assessed by VAS, began to decrease at three months and reached its greatest reduction at six months for the knee and between six and twelve months for the hip. These temporal patterns suggest that functional gains in movement and stiffness may precede maximal analgesic benefit.<\/p>\n\n\n\n

Stratification by radiographic OA grade indicated that better clinical results in terms of mobility and pain reduction were generally observed in younger patients with lower-grade OA, whereas older patients with more advanced disease showed less improvement in mobility but still experienced pain reduction. Table-based analyses of VAS scores by Kellgren\u2013Lawrence and T\u00f6nnis grades further supported the association between less severe preoperative status and greater postoperative benefit. Nonetheless, pain relief was documented even in higher-grade OA, indicating potential symptomatic value across a spectrum of disease severity.<\/p>\n\n\n\n

Quality-of-life outcomes, as measured by the SF-12, showed mean physical and mental component scores in ranges consistent with limited interference of pain and physical or emotional health on daily activities, with many patients reporting high energy levels, minimal feelings of low mood, and generally very good health. At one year, 85% of patients reported being satisfied with the treatment and willing to undergo it again, citing considerable improvement in pain and quality of life. Over a five-year follow-up, a relatively small proportion of patients proceeded to joint replacement surgery.<\/p>\n\n\n\n

From a safety perspective, the use of autologous adipose-derived SVF for OA treatment was reported as safe and feasible, with a low complication rate and no major adverse events at donor or recipient sites. The authors concluded that mesenchymal stem cell\u2013based autologous therapy represents a good option for improving quality of life in patients with mild or moderate OA and may also provide benefit in more severe cases, particularly for individuals who decline surgical treatment, although results remain variable and not fully predictable. These findings, together with independent evidence that minimally manipulated micro-fragmented adipose tissue harvested with small-port cannulas contains viable and proliferative cells suitable for regenerative applications, support the role of autologous regenerative approaches as a promising adjunct in the management of degenerative joint disorders.<\/p>\n\n\n\n

Sources (Bibliography)<\/strong><\/h2>\n\n\n\n
    \n
  • Trentani P, Meredi E, Zarantonello P, Gennai A. Role of Autologous Micro-Fragmented Adipose Tissue in Osteoarthritis Treatment. J Pers Med, 2024.<\/li>\n\n\n\n
  • Gennai A, Bovani B, Colli M, et al. Comparison of Harvesting and Processing Technique for Adipose Tissue Graft: Evaluation of Cell Viability. Int J Regener Med, 2021.<\/li>\n\n\n\n
  • Gennai A, et al. Characterization of Tissue and Stromal Cell for Facial Aging Treatment, 2020.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

    Limitations of symptomatic treatments Degenerative joint diseases such as osteoarthritis (OA) are characterized by progressive degeneration of articular cartilage, joint pain, stiffness, and functional limitation, ultimately leading to disability and impaired quality of life. In OA, the disease process reflects an imbalance between tissue repair and destruction in joints with intrinsically poor healing potential, related […]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[59,8],"tags":[57,58],"_links":{"self":[{"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/posts\/3458"}],"collection":[{"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/comments?post=3458"}],"version-history":[{"count":1,"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/posts\/3458\/revisions"}],"predecessor-version":[{"id":3459,"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/posts\/3458\/revisions\/3459"}],"wp:attachment":[{"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/media?parent=3458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/categories?post=3458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.amsvita.com\/en\/wp-json\/wp\/v2\/tags?post=3458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}